- 432. (New) A method according to claim 390 wherein said selected samples are supply sample for preparation of blood products.
- 433. (New) A method according to any of claims 375, 377, 379 or 381 wherein said samples that are not selected are supply samples for preparation of blood products.
- 434. (New) A method according to claim 383 wherein said samples that are not selected are supply samples for preparation of blood products.
- 435. (New) A method according to claim 385 wherein said samples that are not selected are supply samples for preparation of blood products.
- 436. (New) A method according to claim 387 wherein said samples that are not selected are supply samples for preparation of blood products.

437. (New) A method according to claim 388 wherein said samples that are not selected are supply samples for preparation of blood products.

#### **REMARKS**

Claims 60-437 are now pending in the application. By virtue of this Amendment, claims 261-266 and 308 are amended, and claims 341-437 are added. The newly added claims correspond to claims previously pending in co-owned United States application, serial number 08/441,355. Applicants wish to thank Supervisory Examiner Woodward for the telephonic interview on USSN 08/441,355 during which he stated that Applicants would be allowed to delete claims from USSN 08/441,355 and add the subject matter to the present case. Newly added claims 341-437 reflect the agreement.

The specification is amended to update the status of the applications in the priority statement.

In request to the Examiner's request that formal drawings be filed, please note that the formal drawings were filed January 20, 2003.

Claims 261-266 are amended to correct informalities. Claim 308 is amended to correct a typographical error.

### **Double Patenting Rejections**

Claims 60-340 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-27 of U.S. Patent No. 5,714,596.

Applicants respectfully traverse this rejection and its supporting remarks. In order to expedite prosecution, Applicants herewith submit a terminal disclaimer in order to obviousness-type double patenting rejection of the claims. Accordingly, applicants respectfully request that the obviousness-type double patenting rejection be withdrawn.

Claims 60-340 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-42 of U.S. Patent No. 6,074,816.

Applicants respectfully traverse this rejection and its supporting remarks. In order to expedite prosecution, Applicants herewith submit a terminal disclaimer in order to obviate the obviousness-type double patenting rejection of the claims. Accordingly, applicants respectfully request that the obviousness-type double patenting rejection be withdrawn.

In co-owned case USSN 08/441,355 claims similar to newly added claims 341-437 were rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-6 of U.S. Patent Number 5,863,719. Applicants respectfully traverse this rejection and its supporting remarks. In order to expedite prosecution, Applicants herewith submit a terminal disclaimer in order to obviate the obviousness-type double patenting rejection of the claims. Accordingly, applicants respectfully request that the obviousness-type double patenting rejection be withdrawn.

#### CONCLUSION

Applicants believe that they are entitled to a letters patent, and respectfully solicit the Examiner to expedite prosecution of this patent application to issuance. Should the Examiner

42

Serial No. 08/441

have any questions, the Examiner is encouraged to telephone the undersigned. If the Examiner determines that the claims are not allowable, Applicants request an opportunity to interview the Examiner.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to Deposit Account No. 03-1664 referencing docket no. PP0063.024. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: 14 July 2003

CHIRON CORPORATION Intellectual Property - R440 P.O. Box 8097 Emeryville, CA 94608 (510) 923-2708 (510) 655-3542 (Fax)

Respectfully submitted,

Reg. No. 33,895

## **VERSIONS WITH MARKINGS TO SHOW CHANGES**

# In the Claims:

Claims 261-266 and 308 have been amended as follows:

- 261. (Currently Amended) A polynucleotide according to claim 82 wherein said polynucleotide is an oligonucleotide.
- 262. (Currently Amended) A polynucleotide according to claim 83 wherein said polynucleotide is an oligonucleotide.
- 263. (Currently Amended) A polynucleotide according to claim 84 wherein said polynucleotide is an oligonucleotide.
- 264. (Currently Amended) A polynucleotide according to claim 85 wherein said polynucleotide is an oligonucleotide.
- 265. (Currently Amended) A polynucleotide according to claim 86 wherein said polynucleotide is an oligonucleotide.
- 266. (Currently Amended) A polynucleotide according to claim 87 wherein said polynucleotide is an oligonucleotide.
- 308. (Currently Amended) A composition comprising the polynucleotide of claim 97 wherein said polynucleotide polynucleotide is substantially isolated.